- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
- Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
More ▼
Key statistics
On Wednesday, Apellis Pharmaceuticals Inc (APLS:NSQ) closed at 46.05, 132.22% above the 52 week low of 19.83 set on Aug 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.75 |
---|---|
High | 47.23 |
Low | 44.49 |
Bid | 41.15 |
Offer | 49.45 |
Previous close | 46.05 |
Average volume | 1.91m |
---|---|
Shares outstanding | 120.58m |
Free float | 104.64m |
P/E (TTM) | -- |
Market cap | 5.55bn USD |
EPS (TTM) | -4.48 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼